SLC5A2 and type 2 diabetes mellitus: A recently conducted meta-analysis of eight studies (214 patients in total) of patients receiving SGLT-2 inhibitors for type 2 diabetes mellitus and NAFLD (43) concluded that despite the low-to-moderate quality of evidence from the available pilot and observational studies, SGLT-2 inhibitors appear to improve transaminase levels, fatty liver, and fibrosis, along with providing additional metabolic effects, with the most common adverse effects being genitourinary tract infections.